Analyzing the Price-to-Earnings Ratio of Novartis AG ADR (NVS)

The price-to-earnings ratio for Novartis AG ADR (NYSE: NVS) is above average at 13.21x. The 36-month beta value for NVS is also noteworthy at 0.55. There are mixed opinions on the stock, with 0 analysts rating it as a “buy,” 1 rating it as “overweight,” 2 rating it as “hold,” and 0 rating it as “sell.”

The public float for NVS is 1.96B, and at present, short sellers hold a 0.21% of that float. The average trading volume of NVS on April 04, 2024 was 1.45M shares.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

NVS) stock’s latest price update

The stock of Novartis AG ADR (NYSE: NVS) has decreased by -0.04 when compared to last closing price of 94.41.Despite this, the company has seen a loss of -0.94% in its stock price over the last five trading days. Zacks Investment Research reported 2024-04-02 that In the most recent trading session, Novartis (NVS) closed at $94.41, indicating a -1.52% shift from the previous trading day.

NVS’s Market Performance

NVS’s stock has fallen by -0.94% in the past week, with a monthly drop of -7.45% and a quarterly drop of -6.56%. The volatility ratio for the week is 0.99% while the volatility levels for the last 30 days are 0.90% for Novartis AG ADR. The simple moving average for the past 20 days is -3.48% for NVS’s stock, with a -3.75% simple moving average for the past 200 days.

Analysts’ Opinion of NVS

Many brokerage firms have already submitted their reports for NVS stocks, with BMO Capital Markets repeating the rating for NVS by listing it as a “Market Perform.” The predicted price for NVS in the upcoming period, according to BMO Capital Markets is $114 based on the research report published on February 23, 2024 of the current year 2024.

Morgan Stanley, on the other hand, stated in their research note that they expect to see NVS reach a price target of $114. The rating they have provided for NVS stocks is “Equal-Weight” according to the report published on January 23rd, 2024.

NVS Trading at -6.72% from the 50-Day Moving Average

After a stumble in the market that brought NVS to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -13.25% of loss for the given period.

Volatility was left at 0.90%, however, over the last 30 days, the volatility rate increased by 0.99%, as shares sank -7.57% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.00% lower at present.

During the last 5 trading sessions, NVS fell by -0.94%, which changed the moving average for the period of 200-days by -6.92% in comparison to the 20-day moving average, which settled at $97.38. In addition, Novartis AG ADR saw -6.54% in overturn over a single year, with a tendency to cut further losses.

Stock Fundamentals for NVS

Current profitability levels for the company are sitting at:

  • 0.2 for the present operating margin
  • 0.72 for the gross margin

The net margin for Novartis AG ADR stands at 0.29. The total capital return value is set at 0.14. Equity return is now at value 16.52, with 7.76 for asset returns.

Based on Novartis AG ADR (NVS), the company’s capital structure generated 0.36 points at debt to capital in total, while cash flow to debt ratio is standing at 0.55. The debt to equity ratio resting at 0.56. The interest coverage ratio of the stock is 11.58.

Currently, EBITDA for the company is 18.47 billion with net debt to EBITDA at 0.69. When we switch over and look at the enterprise to sales, we see a ratio of 3.87. The receivables turnover for the company is 5.44for trailing twelve months and the total asset turnover is 0.51. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.16.


In summary, Novartis AG ADR (NVS) has had a bad performance as of late. Analysts have mixed opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.

Related Posts